Comments on: Personalized medicine takes a (tiny) step forward

By: VentureBeat » Big Pharma’s personalized-medicine consortium: Is it for real?

Fri, 28 Sep 2007 19:35:03 +0000

[...] medicine,” for short — has been a long, long time in coming, as I’ve noted here and here. Part of the reason, of course, is that personalizing medicine cuts against the economic [...]

By: VentureBeat » The FDA’s personalized-medicine evangelism

VentureBeat » The FDA’s personalized-medicine evangelism — Thu, 16 Aug 2007 17:43:06 +0000

[...] your medical care based on your genetic profile — has been a long time coming, as I’ve previously written. As it turns out, that’s no fault of the Food and Drug Administration, which has emerged as [...]

By: VentureBeat » Best of the blogosphere on disease genetics

VentureBeat » Best of the blogosphere on disease genetics — Sun, 12 Aug 2007 15:50:33 +0000

[...] an added bonus, it also features two HIV-related posts by yours truly. Check it out. Tagged Alzheimers disease, Gene Genie, left handedness, [...]

By: The Genetic Genealogist - » Gene Genie #13: Into the Future

The Genetic Genealogist - » Gene Genie #13: Into the Future — Sun, 12 Aug 2007 09:02:16 +0000

[...] Personalized medicine takes a (tiny) step forward. David Hamilton at VentureBeat discusses the FDA approval of Selzentry, a new AIDS drug from Pfizer. The drug, however, only works against a particular sub-strain of HIV which binds to a T-cell surface protein called CCR5. Most HIV strains use CXCR4 or a combination of the two. So, not only will OUR genomes be important for personalized medicine, so will the genomes of every pathogen that has infected us. David also discusses a new drug aimed at increasing HIV replication in Koronis: Mutating HIV into extinction. [...]

By: VentureBeat » Is Big Pharma down for the count?

VentureBeat » Is Big Pharma down for the count? — Sat, 11 Aug 2007 00:08:12 +0000

[...] If, in fact, personalized medicine does start to take off — something that’s been a long time in coming — we can probably expect the balance of power to shift even further in biotech’s [...]